ET, Nanox stock was up by a whopping 60%. No cash balance or cash flow is included in the calculation. Cost basis and return based on previous market day close. *Average returns of all recommendations since inception. Nano-X Imaging ( NNOX) shares jumped more than 45% after the FDA approved Nanox.ARC X-ray system. An FDA Approval Could Send This Stock Soaring by August ados_add_placement(9794, 307044, "azk740606", 2629) See our report's 7 new picks today, absolutely FREE. Ann Childress, M.D. If it surprisingly goes in the opposite direction, the stock could have an exaggerated move. In Nanox's annual report, filed Monday, management said it received FDA clearance for its multi-source device on April 28. Our experts who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Nano-X Imaging shares jumped more than 45% after the FDA approved Nanox.ARC X-ray system. Reatacurrently has a Zacks Rank #3 (Hold). The FDA has approved KemPharm's once-daily treatment for ADHD, AZSTARYS. The tablets are expected to be available in the market in the fourth quarter of 2022. KemPharm uses Ligand Activated Therapy (LAT) to discover and develop prodrugs which are used to improve a drug's bioavailability, extend its duration of action, reduce its susceptibility to abuse, and/or increase safety. Friedreich's ataxia is a recessive genetic disorder characterized by the progressive loss of motor abilities and sensation due to nerve damage. *Average returns of all recommendations since inception. Is Reata's stock a buy on this news? Several analysts hiked their price targets on the stock after the FDAs approval for Skyclarys. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now? From there, it intends to make its money on a per-image basis and from its software. EFTR stock has declined 88.9% in the past year. Skyclarys is the first drug to be approved specifically for the treatment of Friedreichs ataxia and is also Reatas first commercial product. After more than a decade of developing a microbiome drug, Seres Therapeutics Inc. has won its first approval from the U.S. Food and Drug Administration. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.